Low Serum Testosterone in Men with Newly Diagnosed Androgen-Deprivation Therapy-Naive Prostate Cancer and Its Relationship to Cardiovascular Risk Factors: A RADICAL-PC Substudy

被引：7

作者：

Pinthus, Jehonathan H. ^{[1
]}

Duivenvoorden, Wilhelmina C. M. ^{[1
]}

Klotz, Laurence ^{[2
]}

Mukherjee, Som D. ^{[3
]}

Siemens, D. Robert ^{[4
]}

Niazi, Tamim ^{[5
]}

Fradet, Vincent ^{[6
]}

Foster, William ^{[6
]}

Duceppe, Emmanuelle ^{[7
]}

Taussky, Daniel ^{[8
]}

Hamilton, Robert ^{[9
]}

Lavallee, Luke ^{[10
,11
]}

Brown, Ian ^{[12
]}

Chin, Joseph ^{[13
]}

Gopaul, Darin ^{[14
]}

Wassef, Anthony ^{[15
]}

Kassouf, Wassim ^{[16
]}

Davis, Margot ^{[17
]}

Violette, Philippe D. ^{[1
,18
]}

Agapay, Steve ^{[19
]}

Balasubramanian, Kumar ^{[19
]}

Mian, Rajibul ^{[19
]}

Rangarajan, Sumathy ^{[19
]}

Sener, Alp ^{[13
]}

Shayegan, Bobby ^{[1
]}

Devereaux, P. J. ^{[18
,19
,20
]}

Leong, Darryl P. ^{[18
,19
,20
]}

机构：

[1] McMaster Univ, Dept Surg, Hamilton, ON, Canada

[2] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Surg, Toronto, ON, Canada

[3] McMaster Univ, Dept Oncol, Hamilton, ON, Canada

[4] Queens Univ, Dept Urol, Kingston, ON, Canada

[5] McGill Univ, Jewish Gen Hosp, Div Radiat Oncol, Montreal, PQ, Canada

[6] Univ Laval, Ctr Hosp Univ Quebec, Quebec City, PQ, Canada

[7] Univ Montreal, Dept Med, Montreal, PQ, Canada

[8] Univ Montreal, Dept Radiat Oncol, Hlth Ctr, Montreal, PQ, Canada

[9] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada

[10] Univ Ottawa, Ottawa, ON, Canada

[11] Ottawa Hosp, Res Inst, Ottawa, ON, Canada

[12] Niagara Hlth Ontario, St Catharines, ON, Canada

[13] Western Univ, Div Urol, London, ON, Canada

[14] Grand River Reg Canc Ctr, Kitchener, ON, Canada

[15] McMaster Univ, Div Cardiol, St Marys Gen Hosp, Kitchener, ON, Canada

[16] McGill Univ, Div Urol, Hlth Ctr, Montreal, PQ, Canada

[17] Univ British Columbia, Div Cardiol, Vancouver, BC, Canada

[18] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada

[19] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada

[20] McMaster Univ, Dept Med, Hamilton, ON, Canada

来源：

JOURNAL OF UROLOGY | 2022年 / 207卷 / 05期

关键词：

cardiovascular diseases; prostatic neoplasms; testosterone; PATHOLOGICAL STAGE; DISEASE; PREDICTOR;

D O I：

10.1097/JU.0000000000002384

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose: Cardiovascular disease is a common cause of death in prostate cancer patients. Low testosterone is associated with increased cardiovascular risk in the general male population. We investigated the relationship between serum testosterone, cardiovascular disease and risk factors in androgen-deprivation therapy-naive prostate cancer patients. Materials and Methods: We performed a cross-sectional analysis of a subgroup of 1,326 androgen-deprivation therapy-naive men from RADICAL-PC (Role of Androgen-Deprivation Therapy In CArdiovascular Disease-A Longitudinal Prostate Cancer study) in whom serum testosterone was measured at baseline. RADICAL-PC is a prospective multicenter cohort study of men (2,565) enrolled within 1 year of prostate cancer diagnosis, or within 6 months of commencing androgen-deprivation therapy for the first time. Cardiovascular risk factors, cancer characteristics and total serum testosterone were collected at baseline. Low testosterone was defined as total serum testosterone <11 nmol/L (<320 ng/dL). A Framingham cardiovascular risk score >= 15 was considered high risk for future cardiovascular events. We performed logistic regression to calculate odds ratios for the association between testosterone and cardiovascular risk. Results: Among 1,326 participants (median age 67 years, range 45-93), 553 (42%) had low testosterone. Low testosterone was associated with existing cardiovascular disease, diabetes, elevated hemoglobin A1c, obesity, hypertriglyceridemia, low high-density lipoprotein cholesterol, hypertension and Framingham score >15. Among patients with low testosterone, the odds ratio for high cardiovascular risk was 1.33 (1.02-1.73) after adjusting for ethnicity, education, alcohol use, cancer characteristics, physical activity and body mass index. Conclusions: Among androgen-deprivation therapy-naive prostate cancer patients, low testosterone is common and associated with increased cardiovascular risk factors.

引用

页码：1020 / 1028

页数：9

共 18 条

[1] Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
Akitake, Naoko
Shiota, Masaki
Obata, Hirofumi
Takeuchi, Ario
Kashiwagi, Eiji
Imada, Kenjiro
Kiyoshima, Keijiro
Inokuchi, Junichi
Tatsugami, Katsunori
Eto, Masatoshi
PROSTATE INTERNATIONAL, 2018, 6 (03) : 104 - 109
[2] Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer
O'Farrell, Sean
Garmo, Hans
Holmberg, Lars
Adolfsson, Jan
Stattin, Par
Van Hemelrijck, Mieke
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (11) : 1243 - +
[3] Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer
Kobayashi, Takeshi
Namitome, Ryo
Hirata, Yu
Shiota, Masaki
Imada, Kenjiro
Kashiwagi, Eiji
Takeuchi, Ario
Inokuchi, Junichi
Tatsugami, Katsunori
Eto, Masatoshi
ANTICANCER RESEARCH, 2019, 39 (06) : 3191 - 3195
[4] The prevalence of metabolic risk factors in black men with prostate cancer undergoing consideration for androgen-deprivation therapy.
Gunnarsson, O.
Basaria, S.
Gignac, G.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[5] Dietary modification to reduce cardiovascular risk factors in patients receiving androgen-deprivation therapy for prostate cancer.
Mega, A. E.
Flynn, M.
Plette, A. M.
Jean, M.
Hue, H.
Safran, H.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[6] Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer
Tward, Jonathan D.
Lenz, Lauren
Gutin, Alexander
Clegg, Wyatt
Kasten, Chelsea R.
Finch, Robert
Cohen, Todd
Michalski, Jeff
Kishan, Amar U.
JCO PRECISION ONCOLOGY, 2024, 8
[7] Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in patients with newly diagnosed prostate cancer referred to androgen-deprivation therapy
Buskbjerg, Cecilie R.
Zachariae, Robert
Buus, Simon
Gravholt, Claus H.
Haldbo-Classen, Lene
Hosseini, S. M. Hadi
Amidi, Ali
CANCER, 2021, 127 (09) : 1495 - 1506
[8] Development and Comparability of a Short Food-Frequency Questionnaire to Assess Diet in Prostate Cancer Patients: The Role of Androgen Deprivation Therapy in CArdiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC) Substudy
Savija, Nevena
Leong, Darryl P.
Pinthus, Jehonathan
Karampatos, Sarah
Shayegan, Bobby
Mian, Rajibul
Rangarajan, Sumathy
Fradet, Vincent
de Souza, Russell J.
Mente, Andrew
Dehghan, Mahshid
CURRENT DEVELOPMENTS IN NUTRITION, 2021, 5 (11):
[9] Androgen deprivation therapy for prostate cancer, measures of adiposity and strength, and adverse cardiovascular outcomes: observations from 3000 men in 5 countries in the RADICAL PC study
Leong, D.
Valle, F.
Delouya, G.
Fradet, V.
Violette, P.
Niazi, T.
Higano, C.
Shayegan, B.
Nain, P.
Hajjar, L.
Iakobishvili, Z.
Oliveira, G.
Avezum, A.
Selvanayagam, J.
Pinthus, J.
EUROPEAN HEART JOURNAL, 2023, 44
[10] SERUM LIPID PROFILE CANNOT IMPROVE AFTER WITHDRAWAL OF ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH PROSTATE CANCER DESPITE THE RECOVERY OF SERUM TESTOSTERONE: IS THE CARDIOVASCULAR RISK STILL REMAINING?
Oka, Ryo
Utsumi, Takanobu
Endo, Takumi
Yano, Masashi
Kamiya, Naoto
Suzuki, Hiroyoshi
JOURNAL OF UROLOGY, 2018, 199 (04): : E696 - E697

← 1 2 →